Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa

dc.contributor.authorTegally, Houriiyah
dc.contributor.authorMoir, Monika
dc.contributor.authorEveratt, Josie
dc.contributor.authorGiovanetti, Marta
dc.contributor.authorScheepers, Cathrine
dc.contributor.authorWilkinson, Eduan
dc.contributor.authorSubramoney, Kathleen
dc.contributor.authorMakatini, Zinhle
dc.contributor.authorMoyo, Sikhulile
dc.contributor.authorAmoako, Daniel G.
dc.contributor.authorBaxter, Cheryl
dc.contributor.authorAlthaus, Christian L.
dc.contributor.authorAnyaneji, Ugochukwu J.
dc.contributor.authorKekana, Dikeledi
dc.contributor.authorViana, Raquel
dc.contributor.authorGiandhari, Jennifer
dc.contributor.authorLessells, Richard
dc.contributor.authorMaponga, Tongai
dc.contributor.authorMaruapula, Dorcas
dc.contributor.authorChoga, Wonderful
dc.contributor.authorMatshaba, Mogomotsi
dc.contributor.authorMbulawa, Mpaphi B.
dc.contributor.authorMsomi, Nokukhanya
dc.contributor.authorNGS-SA consortium
dc.contributor.authorNaidoo, Yeshnee
dc.contributor.authorPillay, Sureshnee
dc.contributor.authorSanko, Tomasz Janusz
dc.contributor.authorSan, James E.
dc.contributor.authorScott, Lesley
dc.contributor.authorSingh, Lavanya
dc.contributor.authorMagini, Nonkululeko A.
dc.contributor.authorSmith-Lawrence, Pamela
dc.contributor.authorStevens, Wendy
dc.contributor.authorDor, Graeme
dc.contributor.authorTshiabuila, Derek
dc.contributor.authorWolter, Nicole
dc.contributor.authorPreiser, Wolfgang
dc.contributor.authorTreurnicht, Florette K.
dc.contributor.authorVenter, Marietjie
dc.contributor.authorChiloane, Georginah
dc.contributor.authorMcIntyre, Caitlyn
dc.contributor.authorO’Toole, Aine
dc.contributor.authorRuis, Christopher
dc.contributor.authorPeacock, Thomas P.
dc.contributor.authorRoemer, Cornelius
dc.contributor.authorPond, Sergei L. Kosakovsky
dc.contributor.authorWilliamson, Carolyn
dc.contributor.authorPybus, Oliver G.
dc.contributor.authorBhiman, Jinal N.
dc.contributor.authorGlass, Allison
dc.contributor.authorMartin, Darren P.
dc.contributor.authorJackson, Ben
dc.contributor.authorRambaut, Andrew
dc.contributor.authorLaguda-Akingba, Oluwakemi
dc.contributor.authorGaseitsiwe, Simani
dc.contributor.authorVon Gottberg, Anne
dc.contributor.authorDe Oliveira, Tulio
dc.contributor.authorBester, Armand Phillip
dc.contributor.authorClaassen, Mathilda
dc.contributor.authorDoolabh, Deelan
dc.contributor.authorMudau, Innocent
dc.contributor.authorMbhele, Nokuzola
dc.contributor.authorEngelbrecht, Susan
dc.contributor.authorGoedhals, Dominique
dc.contributor.authorHardie, Diana
dc.contributor.authorHsiao, Nei-Yuan
dc.contributor.authorIranzadeh, Arash
dc.contributor.authorIsmail, Arshad
dc.contributor.authorJoseph, Rageema
dc.contributor.authorMaharaj, Arisha
dc.contributor.authorMahlangu, Boitshoko
dc.contributor.authorMahlakwane, Kamela
dc.contributor.authorDavis, Ashlyn
dc.contributor.authorMarais, Gert
dc.contributor.authorMlisana, Koleka
dc.contributor.authorMnguni, Anele
dc.contributor.authorMohale, Thabo
dc.contributor.authorMotsatsi, Gerald
dc.contributor.authorMwangi, Peter
dc.contributor.authorNtuli, Noxolo
dc.contributor.authorNyaga, Martin
dc.contributor.authorOlubayo, Luicer
dc.contributor.authorRadibe, Botshelo
dc.contributor.authorRamphal, Yajna
dc.contributor.authorRamphal, Upasana
dc.contributor.authorStrasheim, Wilhelmina
dc.contributor.authorTebeila, Naume
dc.contributor.authorVan Wyk, Stephanie
dc.contributor.authorWilson, Shannon
dc.contributor.authorLucaci, Alexander G.
dc.contributor.authorWeaver, Steven
dc.contributor.authorMaharaj, Akhil
dc.contributor.authorPillay, Yusasha
dc.contributor.authorDavids, Michaela
dc.contributor.authorMendes, Adriano
dc.contributor.authorMayaphi, Simnikiwe
dc.date.accessioned2023-11-23T12:58:49Z
dc.date.available2023-11-23T12:58:49Z
dc.date.issued2022-09
dc.descriptionDATA AVAILABILITY : All of the SARS-CoV-2 genomes generated and presented in this article are publicly accessible through the GISAID platform (https://www.gisaid.org/). The GISAID accession identifiers of the sequences analyzed in this study are provided as part of Supplementary Table 1. Other raw data for this study are provided as a supplementary dataset at https://github.com/krisp-kwazulu-natal/SARSCoV2_South_Africa_Omicron_BA4_BA5. The reference SARS-CoV-2 genome (MN908947.3) was downloaded from the National Center for Biotechnology Information database (https://www.ncbi.nlm.nih.gov/).en_US
dc.description CODE AVAILABILITY : All custom scripts to reproduce the analyses and figures presented in this article are available at https://github.com/krisp-kwazulu-natal/ SARSCoV2_South_Africa_Omicron_BA4_BA5.en_US
dc.description.abstractThree lineages (BA.1, BA.2 and BA.3) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern predominantly drove South Africa’s fourth Coronavirus Disease 2019 (COVID-19) wave. We have now identified two new lineages, BA.4 and BA.5, responsible for a fifth wave of infections. The spike proteins of BA.4 and BA.5 are identical, and similar to BA.2 except for the addition of 69–70 deletion (present in the Alpha variant and the BA.1 lineage), L452R (present in the Delta variant), F486V and the wild-type amino acid at Q493. The two lineages differ only outside of the spike region. The 69–70 deletion in spike allows these lineages to be identified by the proxy marker of S-gene target failure, on the background of variants not possessing this feature. BA.4 and BA.5 have rapidly replaced BA.2, reaching more than 50% of sequenced cases in South Africa by the first week of April 2022. Using a multinomial logistic regression model, we estimated growth advantages for BA.4 and BA.5 of 0.08 (95% confidence interval (CI): 0.08–0.09) and 0.10 (95% CI: 0.09–0.11) per day, respectively, over BA.2 in South Africa. The continued discovery of genetically diverse Omicron lineages points to the hypothesis that a discrete reservoir, such as human chronic infections and/or animal hosts, is potentially contributing to further evolution and dispersal of the virus.en_US
dc.description.departmentMedical Virologyen_US
dc.description.librarianam2023en_US
dc.description.sdgSDG-03:Good heatlh and well-beingen_US
dc.description.sponsorshipThe South African Medical Research Council (SAMRC) with funds received from the National Department of Health. Sequencing activities for the National Institute for Communicable Diseases (NICD) are supported by a conditional grant from the South African National Department of Health as part of the emergency COVID-19 response; a cooperative agreement between the NICD of the NHLS and the US Centers for Disease Control and Prevention (CDC) (U01IP001048 and 1 NU51IP000930); the African Society of Laboratory Medicine (ASLM) and Africa Centers for Disease Control and Prevention through a sub-award from the Bill and Melinda Gates Foundation (grant number INV-018978); the UK Foreign, Commonwealth and Development Office and Wellcome (221003/Z/20/Z); and the UK Department of Health and Social Care, managed by the Fleming Fund and performed under the auspices of the SEQAFRICA project. This research was also supported by the Coronavirus Aid, Relief, and Economic Security Act (CARES ACT) through the CDC and COVID International Task Force (ITF) funds through the CDC under the terms of a subcontract with the African Field Epidemiology Network (AFENET) (AF-NICD-001/2021). Sequencing activities at KRISP and the Centre for Epidemic Response and Innovation are supported, in part, by grants from the World Health Organization, the Rockefeller Foundation (HTH 017), the Abbott Pandemic Defense Coalition (APDC), the US National Institutes of Health (U01 AI151698) for the United World Antivirus Research Network (UWARN) and the INFORM Africa project through IHVN (U54 TW012041) and the South African Department of Science and Innovation (SA DSI) and the SAMRC under the BRICS JAF (2020/049). Sequencing at the Botswana Harvard AIDS Institute Partnership was supported by funding from the Bill and Melinda Gates Foundation, the Foundation for Innovation in Diagnostics, the National Institutes of Health Fogarty International Centre (3D43TW009610-09S1) and the HHS/NIH/ National Institute of Allergy and Infectious Diseases (NIAID) (5K24AI131928-04 and 5K24AI131924-04).en_US
dc.description.urihttp://www.nature.com/naturemedicineen_US
dc.identifier.citationTegally, H., Moir, M., Everatt, J. et al. 2022, 'Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa', Nature Medicine, vol. 28, pp. 1785-1790. DOI : 10.1038/s41591-022-01911-2.en_US
dc.identifier.issn1078-8956 (print)
dc.identifier.issn1546-170X (online)
dc.identifier.other10.1038/s41591-022-01911-2
dc.identifier.urihttp://hdl.handle.net/2263/93417
dc.language.isoenen_US
dc.publisherNature Researchen_US
dc.rights© The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License.en_US
dc.subjectVirusen_US
dc.subjectInfectionsen_US
dc.subjectCOVID-19 pandemicen_US
dc.subjectCoronavirus disease 2019 (COVID-19)en_US
dc.subjectSouth Africa (SA)en_US
dc.subjectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)en_US
dc.subjectOmicronen_US
dc.subjectSDG-03: Good health and well-beingen_US
dc.titleEmergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africaen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
Tegally_Emergence_2022.pdf
Size:
6.21 MB
Format:
Adobe Portable Document Format
Description:
Article
Loading...
Thumbnail Image
Name:
Tegally_EmergenceSuppl_2022.xlsx
Size:
1.33 MB
Format:
Microsoft Excel XML
Description:
Supplementary Material

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: